Evox Therapeutics
King Charles House
Park End Street
Oxford
OX1 1JD
United Kingdom
Website: https://www.evoxtherapeutics.com/
About Evox Therapeutics
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of biotherapeutics.
YEAR FOUNDED:
2016
LEADERSHIP:
Founders: Matthew Wood, Per Lundin and Samir EL Andaloussi
CEO: Antonin de Fougerolles
COO: Per Lundin
JOBS:
Please click here for Evox job opportunities.
CLINICAL TRIAL:
36 articles about Evox Therapeutics
-
BioSpace Movers & Shakers, May 29
5/29/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Evox Therapeutics Appoints Martin Andrews as Non-Executive Director
5/27/2020
Evox Therapeutics Ltd, a leading exosome therapeutics company, is pleased to announce the appointment of Martin Andrews as a Non-Executive Director.
-
Evox Therapeutics Appoints Dr Sonya Montgomery as Chief Medical Officer
5/19/2020
Highly experienced physician with an excellent track record in clinical development at early stage biotech and big pharma
-
Evox Therapeutics Appoints Paul Carter as Non-executive Chairman
5/14/2020
A seasoned executive with an extensive track record of global leadership in life sciences
-
CEVEC signs license agreement for the development and commercialization of exosomes for therapeutic use
4/16/2020
CEVEC Pharmaceuticals GmbH announced the signing of a license agreement with Evox Therapeutics, Ltd. for the development and commercialization of therapeutic exosomes using CEVEC’s proprietary CAP® technology.
-
Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration
3/26/2020
Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox's proprietary exosome technology Partnership encompasses up to five rare disease targets, including Evox's Niemann-Pick Type C programme, with Takeda assuming responsibility for its clinical development [26-March-2020]
-
The two companies plan to focus their efforts on targeting several rare diseases.
-
Evox Therapeutics Granted Key Exosome Patents Covering RNA Therapeutics and Targeted Drug Delivery
8/7/2019
Evox Therapeutics Ltd, a leading exosome therapeutics company, is pleased to announce that the Company has been granted three key patents by the United States Patent and Trademark Office and the European Patent Office.
-
Evox Therapeutics Expands Leadership Team With the Appointment of Two Experienced Life Sciences Executives
5/9/2019
Evox Therapeutics Ltd, a leading exosome therapeutics company, is pleased to announce the appointments of Bo Kara as VP Process Development and Simon Dew as VP of Business Development.
-
Evox Therapeutics Awarded £1.5 Million in Funding From Innovate UK
3/22/2019
Proceeds will support advancement of an exosome therapy to treat a urea cycle disorder
-
Evox Therapeutics Appoints Edwin Moses as Non-Executive Chairman
12/20/2018
Highly experienced life sciences executive with a track record of overseeing strong company growth and value creation
-
Evox Therapeutics to Expand Its Work on Cell-targeted Delivery of Nucleic Acid-based Drugs
12/10/2018
Funding received from the Bill & Melinda Gates Foundation
-
Evox Therapeutics Named in The Sunday Times Fast Track Disruptors to Watch
12/3/2018
Prestigious accolade recognises the potential impact of the Company's disruptive exosome drug platform
-
Evox Therapeutics Wins Funding From Duchenne UK to Explore Exosome-Mediated Delivery of Dystrophin
11/13/2018
Targeted delivery of dystrophin has the potential to be a highly effective treatment for Duchenne muscular dystrophy
-
Evox Therapeutics Completes £35.5 Million Series B Financing
9/3/2018
Proceeds will advance transformative exosome therapeutics pipeline towards the clinic
-
Evox Therapeutics to Collaborate With Boehringer Ingelheim on Exosome-Mediated Drug Delivery
12/19/2017
The collaboration is part of Boehringer Ingelheim's RBB initiative that explores emerging science and technologies for and beyond its core therapeutic areas to create new opportunities in disease indications of high medical need.